LAUSR

Objectives: To investigate the prognostic value of demographic and clinicopathologic factors including CA-125 levels in patients with stage I epithelial ovarian carcinoma. Methods: Data was obtained from the National Cancer Database (NCDB PUF 2016). Patients were diagnosed with stage I epithelial ovarian cancer between 2004 and 2015. CA-125 results were reported as abnormal if they were ≥35 units/mL before treatment. Kaplan-Meier method, log-rank test, and multivariate Cox proportional hazards modeling were used for statistical analyses. Results: Of 15,882 patients with stage I epithelial ovarian carcinoma, the median age was 55 (range 18-90). The majority of patients were White (80.4%) and the remainder were Hispanic (6.4%), Black (6.1%), and Asian (5%). Stage IA, IB, IC, and stage I NOS were found in 54.2%, 3.8%, 36.3%, 5.7% of patients, respectively. There were 25.2% with endometrioid carcinoma, 20.9% with serous carcinoma, 20.7% with mucinous carcinoma, 15.6% with clear cell carcinoma and 17.6% with other epithelial subtypes. The 5-year overall survival (OS) was 86.0%. Black race was associated with worse OS at 82.6% compared to 85.6% of Whites (P=0.024). Those with higher substage IC vs IA and IB had worse survivals (82.7% vs 88.4% and 85.3%; P Conclusions: Our data suggest that pretreatment CA-125 is an independent prognostic factor in women with stage I epithelial ovarian cancer. Other predictors of survival include race, region, sub-stage, cell type, grade, and LVSI.